Smoking Cessation within tobacco control: Own contributions
|
|
- Melvin Lang
- 5 years ago
- Views:
Transcription
1 Smoking Cessation within tobacco control: Own contributions C T Bolliger FHS, US 25 May 2012
2
3 Projected annual tobacco-related deaths Year Total 1.World 3.World Mackay JL. Tuber Lung Dis 1994;75: st century mortality prediction: 1 Billion
4 Reference: Joossens L, Raw M. The Tobacco Control Scale: a new scale to measure country activity. Tob Control 2006; full PDF available at:
5 Three-pronged approach Counselling Hospital QuitSupport (HQS) in Switzerland Regional smoking cessation Clinics in SA Guidelines For Africa/Middle East Ali AY. Respiration. 2012;83(5): Pharmaceutical Aids Smoking Reduction Varenicline VarNic Study
6 Map of Switzerland Bolliger CT. Swiss Med Wkly Jul 26;138(29-30):427-31
7 WEB Search/Phone call Offers for 3 risk factors: Obesity (nutrition, alimentation, Ernaehrung) Hypertension Smoking 102 US hospitals: web sites: 30%, phone call:47% Denny JT. CHEST 2002;122:692 Bolliger CT. Swiss Med Wkly Jul 26;138(29-30):427-31
8 Personal Visits to Hospitals Letter to hospital director and head of Internal Medicine (or medical director) Describe project Announce visit of HQS team (CTB, XvB) Visit all hospitals 10/05 1/06 explain project Motivate for establishment of smoking cessation clinic Bolliger CT. Swiss Med Wkly Jul 26;138(29-30):427-31
9 Medical offer WEB Telephone Visit Obesity 29/44 (65.9%) 42/44 (95.5%) 42/44 (95.5%) Hypertension 19/44 (43.2%) 43/44 (97.7%) 43/44 (97.7%) Smoking 6/44 (13.6%) 10/44 (22.7%) 9/44 (20.5%) Bolliger CT. Swiss Med Wkly Jul 26;138(29-30):427-31
10 Smoking Cessation Clinics in SA Planned: TAH, Paarl, Worcester..and primary care centres around peninsula In cooperation with Mark Cotton, Bob Mash NIH refused to look at R01 proposal because of lack of Northern hemisphere expert what a joke! we are now looking at Swiss connections
11
12 Nicotine Replacement Therapy (NRT)
13 Smoking Reduction with NRT 400 smokers, 18y, 15 cig/day, CO 10ppm unwilling or unable to quit Recommended: 50% no of cig/d 200 nicotine/200 placebo inhaler 18/12 Success: 50% no of cig/d, any CO Bolliger BMJ 2000;321:329-33
14 Smoking Reduction with NRT Results (sustained reduction): month n (%) active n (%) placebo p 4 52 (26) 18 (9) < (13) 8 (4) (9.5) 6 (3) Bolliger BMJ 2000;321:329-33
15 Varenicline
16 Mechanism of Action of Nicotine in the Central Nervous System b2 b2 a4 b2 a4 a4b2 nicotinic acetylchol ine receptor (nachr) Nicotine binds preferentially to nachrs in the central nervous system; one key area is the α4β2 nicotinic receptor in the VTA After nicotine binds to the α4β2 nachr in the VTA, dopamine is released in the nacc which is believed to be linked to reward
17 Varenicline (Champix ) Specifically developed for smoking cessation Partial agonist of the a4b2-nicotinic acetylcholine receptor, combines agonistic and antagonistic properties in one drug As agonist: reduces withdrawal symptoms As antagonist: blocks reward pathway after nicotine uptake
18 Varenicline: A Highly Selective a4b2 Nicotinic Acetylcholine Receptor Partial Agonist Nicotine Varenicline Binding of nicotine at the α4β2 nicotinic acetylcholine receptor (nachr) in the VTA is believed to cause release of dopamine at the nacc 1 1. Picciotto MR, et al. Nicotine Tob Res. 1999;Suppl 2:S121-S Coe JW, et al. J Med Chem. 2005;48: As a partial agonist of α4β2 nachrs, varenicline: Stimulates dopamine release from the VTA at a lower level than nicotine Blocks nicotine antagonistically from binding these receptors 2
19 7-Day Point Prevalence Abstinence Gonzales, D. et al. JAMA 2006;296:47-55 Copyright restrictions may apply.
20 Does it work in SA? A multicenter, randomized, double-blind, placebo-controlled clinical trial conducted at 42 sites in 11 countries Latin America: Brazil, Colombia, Costa Rica, Mexico, Venezuela Africa: South Africa, Egypt Middle East: Jordan, Lebanon, Saudi Arabia, United Arab Emirates Treatment 12 weeks of treatment with varenicline (0.5 mg once daily for 3 days, 0.5 mg BID for 4 days, then 1.0 mg BID) or placebo
21 Study Design (1080) Treatment Phase Varenicline (1 mg BID, up-titration during first week) Non-treatment Phase Screening Visit Week 1 Placebo Primary Endpoint: 4-week continuous abstinence rate Weeks 9 12 (CO-confirmed) Baseline Randomization Target Quit Date at Week 1 visit Secondary Endpoint: Continuous abstinence rate Weeks 9 24 (CO-confirmed) Clinic Visits Weeks 2, 3, 4, 6, 8, 10, 12, 13, 16, 20 and 24 Telephone calls TQD+3, Weeks 14, 18 and 22
22 Continuous Abstinence (%) CO-Confirmed CARs Bolliger CT. Clin Ther. 2011;33(4): OR: 5.76* (95% CI 3.74 to 8.88), P<0.0001* Varenicline 1 mg BID (n=390) Placebo (n=198) OR: 4.78* (95% CI 2.97 to 7.68), P<0.0001* Weeks 9-12 Weeks 9-24 *Odds ratio and P values obtained from logistic regression model including the main effects of treatment and country
23 VarNic: VarNic study: varenicline ± nicotine patch: Never done SA multicenter study (n=438, 7 sites, 6/12) 5 Cape Town, 1 JHB, 1 Durban Last patient in: 31/3/2012: out: 30/9/2012 First impressions: Good safety
24 ...and do not forget...
SMOKING CESSATION WORKSHOP. Dr Mark Palayew December
SMOKING CESSATION WORKSHOP Dr Mark Palayew December 5 2016 Conflicts of Interest None Case 1 Mr. T is a 55 year old smoker 2 packs/day He has been smoking continuously since age 16 When he wakes up at
More informationVarenicline Update. Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, Norway
Varenicline Update Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, orway October 23, 2015 Disclosures related to smoking cessation: Pfizer, Mceil, ovartis Binding
More information3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine
How can there be a warning regarding concomitant use of varenicline with nicotine replacement therapy yet patients can be on varenicline and smoke concurrently? April 20, 2017 The United States (US) Preventive
More informationVarenicline and Other Pharmacotherapies for Tobacco Dependence
Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism
More informationKeywords: tobacco, cigarette smoke, nicotine, dopamine, smoking cessation, acethylcholine, varenicline (champix )
Review Article and Clinical Experience: ENICLINE (CHAMPIX ) : A BREAKTHROUGH FOR SMOKING CESSATION TREATMENT (An α4ß2 Nicotinic Acethylcholine Receptor Partial Agonist) Askandar Tjokroprawiro Diabetes
More informationEffective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More informationTobacco smoking is the leading preventable. Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis Mitchell Nides, PhD; Elbert D. Glover, PhD, FAAHB; Victor I. Reus, MD; Arden G. Christen, DDS, MSA, MA; Barry J. Make,
More informationPharmacotherapy for Tobacco Dependence Treatment
Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org
More informationTreating Tobacco Use:
Treating Tobacco Use: Optimizing for the Best Outcomes Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org Primary
More informationSmoking Cessation: Where Are We Now? Nancy Rigotti, MD
Smoking Cessation: Where Are We Now? Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org OVERVIEW The challenge for
More informationBackground. Abstinence rates associated with varenicline
What are the range of abstinence rates for varenicline for smoking cessation? Do they differ based on treatment duration? Are there any studies utilizing 3-4 months of varenicline treatment? Background
More informationSmoking Cessation. Hassan Sajjad Pulmonary & Critical Care
Smoking Cessation Hassan Sajjad Pulmonary & Critical Care Objectives Burden of Smoking Health Impacts of Smoking Smoking Cessation Motivational Interviewing Nicotine Replacement Therapy Bupropion Varenicline
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationSmoking Cessation: Good News at Last!
Smoking Cessation: Good News at Last! Andrew L. Pipe, CM, MD The Minto Prevention & Rehabilitation Centre University of Ottawa Heart Institute Ottawa, Ontario. Canada apipe@ottawaheart.ca Declaration of
More informationDisclaimers. Smoking and Smoking Cessation. Worldwide. Objectives. Statistics at Home. Smoking Epidemic 16/10/2017
Disclaimers Smoking and Smoking Cessation Dr. Janneke Gradstein CCFP(EM) Yarmouth, NS Received CHA Funding 6 th Annual Ottawa Conference: State of the Art Clinical Approaches to smoking cessation. References
More informationHelping People Quit Tobacco
Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research
More informationEfficacy and Safety of Varenicline for Smoking Cessation
The American Journal of Medicine (2008) Vol 121 (4A), S32 S42 J. Taylor Hays, MD, Jon O. Ebbert, MD, and Amit Sood, MD Nicotine Dependence Center, Mayo Clinic College of Medicine, Mayo Clinic, Rochester,
More informationSmokeless Tobacco Cessation: Review of the evidence. Raymond Boyle, PhD Tobacco Summit 2007 MDQuit.org
Smokeless Tobacco Cessation: Review of the evidence Raymond Boyle, PhD Tobacco Summit 2007 MDQuit.org Previous Reviews of ST evidence Hatsukami and Boyle (1997) Evidence base is limited by small sample
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
Learning Objectives TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of Pharmacy Learning
More informationSmoking Cessation Strategies in 2017
Smoking Cessation Strategies in 2017 Robert Schilz DO, PhD, FCCP Division of Pulmonary, Critical Care and Sleep Medicine Director of Lug Transplantation University Hospitals of Cleveland Case Western University
More informationEvidence-based Practice
Evidence-based Practice Michael V. Burke, EdD Assistant Professor of Medicine Treatment Program Coordinator Mayo Clinic Nicotine Dependence Center May, 2013 Learning objectives At the end of this presentation
More informationSMOKING CESSATION IS HARD
POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping
More informationEvaluation of Asthma Management in Middle EAst North Africa Adult population
STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:
More information1. Describe the benefits of smoking cessation. 2. List the withdrawal symptoms of quitting smoking. Cessation
Time to Butt Out Adil Virani, BSc (Pharm), Pharm D, FCSHP Objectives After this presentation, participants should be able to: 1. Describe the benefits of smoking cessation 2. List the withdrawal symptoms
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationIf treatment for tobacco addiction was evidence-based, what would it look like? Robert West University College London YORK, November 2005
If treatment for tobacco addiction was evidence-based, what would it look like? Robert West University College London YORK, November 2005 Outline What is tobacco addiction and what is the goal of treatment?
More informationA randomized trial comparing two Internetbased smoking cessation programs
A randomized trial comparing two Internetbased smoking cessation programs Jean-François ETTER Faculty of Medicine, University of Geneva, Switzerland E-mail: Jean-Francois.Etter@unige.ch Acknowledgements
More informationMonth/Year of Review: March 2014 Date of Last Review: April 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationDrug Use Evaluation: Smoking Cessation
Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239-4501 Phone 503-947-5220 Fax 503-494-1082 Drug Use Evaluation: Smoking Cessation Tobacco cessation
More informationUpdate on Medications for Tobacco Cessation
Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction
More informationSmoking Cessation Interventions In Hospital Settings: Implementing the Evidence
Smoking Cessation Interventions In Hospital Settings: Implementing the Evidence Nancy Rigotti, MD Tobacco Research & Treatment Center, General Medicine Division, Massachusetts General Hospital, Harvard
More informationSupplementary Online Content
Supplementary Online Content Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical
More informationMYTH #1. Nicotine is a harmful, medically dangerous drug. Nicotine: Myths, Realities & Treatment OBJECTIVES FACT. CSAM Board Review Course, 10/23/08
Nicotine: Myths, Realities & Treatment CSAM Board Review Course, Newport Beach, CA Presented by David P.L. Sachs, MD Director, Palo Alto Center for Pulmonary Disease Prevention & Clinical Associate Professor,
More informationHow best to get your patients to stop smoking. Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London
How best to get your patients to stop smoking Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London 1 2 Smoking can cause at least 14 different types of cancer 3 Smokers want to stop All smokers
More informationPrimary Care Smoking Cessation. GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco
Primary Care Smoking Cessation Dr John McMenamin GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco Target or Tickbox? The Tobacco health target:
More informationPulmonary Year in Review
Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures
More informationSmoking Cessation A Clinicians Perspective. Jeff Wilson, MD
Smoking Cessation A Clinicians Perspective Jeff Wilson, MD Overview Tobacco control what we have accomplished and the road ahead Role of the health care professional Using pharmacotherapy Electronic cigarettes
More informationSAFETY E-CIGS: CLINICAL STUDIES
SAFETY E-CIGS: CLINICAL STUDIES SAFETY ECIGS: clinical studies Source: Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: A systematic review. Ther Adv Drug
More informationAn Evolving Perspective on Smoking Cessation Therapies
An Evolving Perspective on Smoking Cessation Therapies Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe,
More informationTobacco treatment for people with serious mental illness (SMI)
Tobacco treatment for people with serious mental illness (SMI) An opportunity to close the mortality gap Massachusetts Mental Health Center 1 National Resource Center for Academic Detailing A compelling
More informationHealth Promotion Service Project Overview
Health Promotion Service Project Overview TITLE NATIONAL TARGETS (e.g. To reduce the under 18 conception rate by 50% by 2010 ) Cornwall & Isles of Scilly Stop Smoking Service Reduce smoking prevalence
More informationSmoking Cessation: Treating Tobacco Dependence
Smoking Cessation: Treating Tobacco Dependence Pat Folan, RN Center for Tobacco Control Pulmonary Medicine NS-LIJ Health System NYS DOH Tobacco Control Program Treating Tobacco Dependence Center for Tobacco
More informationSMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami.
SMOKING CESSATION 08 Recommendations 5As Approach to Intervention Stages of Change Assisting the Smoker Pharmacotherapy Contributor Dr. Saifuz Sulami Advisor Dr. Audrey Tan 79 nhg_guideline_14102010_1112.indd
More informationPopulation-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge
Population-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge Harlan R. Juster, Ph.D. Director, Bureau of Tobacco Control New York State Department of health November 6, 2013 Learning
More informationGenetics of Nicotine Dependence & Impact of Smoking on Bladder Cancer Risk and Prognosis
Genetics of Nicotine Dependence & Impact of Smoking on Bladder Cancer Risk and Prognosis BCAN August 2014 Helena Furberg Barnes Assistant Attending Epidemiologist www.mskcc.org Current smoking in the US
More informationEVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO
EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO Lena Matthias Gray, MSA, CTTS-M University of Michigan MHealthy Tobacco Consultation Service Overview of Tobacco Use The World Health Organization
More informationCost-effectiveness of smoking cessation in Australia with varenicline, a novel pharmacotherapy
Cost-effectiveness of smoking cessation in Australia with varenicline, a novel pharmacotherapy Alissa Brown 1, Kate Webb 1, Hansoo Kim 1, Danny Liew 2 1 Pfizer Australia Pty Ltd 2 St Vincent s Hospital,
More informationHeather Dacus, DO, MPH Preventive Medicine Physician Director, Bureau of Chronic Disease Control New York State Department of Health
Heather Dacus, DO, MPH Preventive Medicine Physician Director, Bureau of Chronic Disease Control New York State Department of Health Disclosure Heather Dacus has no real or perceived vested interests that
More informationTime to Butt Out. Adil Virani, BSc (Pharm), Pharm D, FCSHP
Time to Butt Out Adil Virani, BSc (Pharm), Pharm D, FCSHP Objectives After this presentation, participants should be able to: 1. Describe the benefits of smoking cessation 2. List the withdrawal symptoms
More informationDepression and anxiety as risk factors for failure in smoking cessation attempt among personnel of Tartu University Hospital
Depression and anxiety as risk factors for failure in smoking cessation attempt among personnel of Tartu University Hospital 2010-2012 Ülle Ani 1, Kersti Pärna 2, Inge Ringmets 2, Tiina Mändla 3. 1 Tartu
More informationEffectiveness of Providing Free Nicotine Replacement Therapy Through Ontario Family Health Teams: Preliminary Findings
Effectiveness of Providing Free Nicotine Replacement Therapy Through Ontario Family Health Teams: Preliminary Findings Dr. Peter Selby MBBS, CCFP, FCFP, June 6, 2012 Justine Mascarenhas MSc, Janine Fitzpatrick
More informationAdolescents and Tobacco Cessation
Adolescents and Tobacco Cessation Jonathan D. Klein, MD, MPH American Academy of Pediatrics Julius B. Richmond Center and the University of Rochester Rochester, NY Goal To review current evidence and perspectives
More informationSmoking Cessation Strategies for the 21st Century
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/smoking-cessation-strategies-for-the-21stcentury/3862/
More informationTobacco & Nicotine: Addiction and Treatment
Tobacco & Nicotine: Addiction and Treatment Tim McAfee, MD, MPH Chief Medical Officer - Free & Clear 206-876-2551 - tim.mcafee@freeclear.com Affiliate Assistant Professor, University of Washington, School
More informationQuitting patterns and success rates of a tobacco cessation program led by New Mexico Pharmaceutical Care Foundation
University of New Mexico UNM Digital Repository Pharmaceutical Sciences ETDs Electronic Theses and Dissertations 8-27-2012 Quitting patterns and success rates of a tobacco cessation program led by New
More informationVARENICLINE: NEW TREATMENT WITH EFFICACY IN SMOKING CESSATION
Drugs of Today 2007, 43 (2): 65-75 Copyright 2007 PROUS SCIENCE CCC: 1699-3993/2007 DOI: 10.1358/dot.2007.43.2.1069956 Available on the web at: www.prous.com/journals VARENICLINE: NEW TREATMENT WITH EFFICACY
More information7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5
7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5 2 / 5 3 / 5 7 day quit smoking pdf 7 Your guide to quitting smoking This guide is for smokers who want to quit and stay quit. Just like
More informationTitle: Varenicline for Smoking Cessation. Date: June 4, Context and policy issues:
Title: Varenicline for Smoking Cessation Date: June 4, 2007 Context and policy issues: The prevalence of smoking in Canada continues to drop, according to the 2005 Canadian Tobacco Use Monitoring Survey.
More informationRimonabant for treating tobacco dependence
REVIEW Rimonabant for treating tobacco dependence Michael B Steinberg 1,2 Jonathan Foulds 1 1 University of Medicine and Dentistry of New Jersey School of Public Health, Tobacco Dependence Program, New
More informationReport by the Convention Secretariat. Purpose of the document
66 Conference of the Parties to the WHO Framework Convention on Tobacco Control Eighth session Geneva, Switzerland, 1 6 October 2018 Provisional agenda item 6.5 FCTC/COP/8/10 27 June 2018 Progress report
More informationA multicenter tobacco cessation program in acute coronary syndrome
A multicenter tobacco cessation program in acute coronary syndrome PD Nicolas Rodondi, MD, MAS Research Fellow: Reto Auer, MD Head of the Cardiovascular Prevention & Lipid Clinic Department of Ambulatory
More informationWanting to Get Pregnant
Continuing Medical Education COPD Case Presentation LEARNING OBJECTIVES Those completing this activity will receive information that should allow them to Assist a patient in developing a quit plan; Advise
More informationThis standard is not designed to be prescriptive of how, when or in what format training is delivered although, some guidelines are included.
Using Medicines (or medicines refresher) This is a training standard developed for the National Training Service (NTS) Alliance. This standard has been written in consultation with subject matter experts.
More informationSmoking cessation and weight gain
Smoking cessation and weight gain David McFadden, MD, MPH Mayo Clinic Nicotine Dependence Center 2012 MFMER slide-1 Disclosures I presented lectures for Pfizer-sponsored tobacco treatment seminars in Brazil,
More informationInterprofessional Primary Care Medical Directive for Smoking Cessation
Insert Logo or Org Name Here Interprofessional Primary Care Medical Directive for Smoking Cessation Adapted from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 14,
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationTobacco Use and Cessation in Psychiatric Patients
Tobacco Use and Cessation in Psychiatric Patients John Spangler, MD, MPH Professor of Family Medicine Wake Forest School of Medicine NCPA, October 2015 Disclosure I have no relevant financial relationship
More informationBreaking the Chains of Nicotine Dependence - A Breakthrough Approach
Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationA double-blind study evaluating the long-term safety of varenicline for smoking cessation*
Current Medical Research and Opinion Vol. 23, No. 4, 2007, 793 801 2007 LibraPharm Limited 0300-7995 doi:10.1185/030079907x182185 All rights reserved: reproduction in whole or part not permitted ORIGINAL
More informationPharmacologic Therapy for Tobacco Use & Dependence
Pharmacologic Therapy for Tobacco Use & Dependence Thomas Gauvin, MA, TTS Mayo Clinic Nicotine Dependence Center Rochester, MN 2013 MFMER slide-1 Learning Objectives Understand the 7 first line medications
More informationTobacco Cessation: Best Practices in Cancer Treatment. Audrey Darville, PhD APRN, CTTS Certified Tobacco Treatment Specialist UKHealthCare
Tobacco Cessation: Best Practices in Cancer Treatment Audrey Darville, PhD APRN, CTTS Certified Tobacco Treatment Specialist UKHealthCare Objectives 1. Describe the current state of tobacco use treatment
More informationPharmacologic Therapy for Tobacco Use & Dependence Nicotine Replacement Therapy (NRT) and Bupropion
Pharmacologic Therapy for Tobacco Use & Dependence Nicotine Replacement Therapy (NRT) and Bupropion Jennifer Bluem Moran, MA, TTS Mayo Clinic Nicotine Dependence Center Rochester, MN 2013 MFMER slide-1
More informationPhysical activity as an aid for smoking cessation
Physical activity as an aid for smoking cessation - study David Faeh, MD Christiane Ruffieux, PhD Jacques Cornuz, MD, MPH Background Prevalence of smoking in Switzerland: 33% Most smokers cumulate both
More informationEffect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt
Psychopharmacology (2008) 197:371 377 DOI 10.1007/s00213-007-1041-3 ORIGINAL INVESTIGATION Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationA systems approach to treating tobacco use and dependence
A systems approach to treating tobacco use and dependence Ann Wendland, MSL Policy Analyst & Cessation Programs Manager NYSDOH Bureau of Tobacco Control ann.wendland@health.ny.gov A systems approach to
More informationSmoking Cessation. Disclosures. Thank You. None
Smoking Cessation Dr. Jamie Kellar; BSc, BScPhm, PharmD Clinician Educator Centre for Addiction and Mental Health Assistant Professor Leslie Dan Faculty of Pharmacy Disclosures None Thank You Several slides
More informationPharmacological interventions for smoking cessation: an overview and network meta-analysis (Review)
Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review) Cahill K, Stevens S, Perera R, Lancaster T This is a reprint of a Cochrane review, prepared and maintained
More informationState of the Science in the treatment of nicotine dependence Terry A. Rustin, M.D.
State of the Science in the treatment of nicotine dependence 2006 Terry A. Rustin, M.D. State of the Science Public health issues Effects of nicotine Smoking cessation New chemotherapeutic agents Nicotine
More informationVarenicline for smoking cessation: a review
Review article GP Rauniar 1, A Misra 2, DP Sarraf 2 1 Professor and Head, 2 Assistant Professor, Department of Clinical Pharmacology and Therapeutics, B.P. Koirala Institute of Health Sciences, Dharan,
More informationBest practice for brief tobacco cessation interventions. Hayden McRobbie The Dragon Institute for Innovation
Best practice for brief tobacco cessation interventions Hayden McRobbie The Dragon Institute for Innovation Disclosures I am Professor of Public Health Interventions at Queen Mary University of London
More informationReal-World Data for Enhancement of a National Smoking Cessation Intervention
Real-World Data for Enhancement of a National Smoking Cessation Intervention SmokefreeTXT Erik Augustson, PhD, MPH Director, Smokefree.gov Initiative Tobacco Control Research Branch Behavioral Research
More informationEvidence Based Approaches for Treating the Unmotivated Smoker
Evidence Based Approaches for Treating the Unmotivated Smoker Jessica W. Cook, PhD Center for Tobacco Research and Intervention (UW-CTRI) University of Wisconsin School of Medicine and Public Health William
More informationTREATMENT OF NICOTINE DEPENDENCE
TREATMENT OF NICOTINE DEPENDENCE Introduction Most commonly used substance the world over. Largest cause of preventable death worldwide. Leading causes of smoking related death Cardiovascular diseases
More informationBest Practices in Tobacco Treatment IDN
Best Practices in Tobacco Treatment IDN 6.27.18 Objectives Project SCUM was a plan proposed in 1995 by R. J. Reynolds Tobacco Company (RJR) to sell cigarettes to members of the "alternative lifestyle"
More informationHow to help your patient quit smoking. Christopher M. Johnson MD, PhD
How to help your patient quit smoking Christopher M. Johnson MD, PhD Outline Smoking and its effects on IBD CD UC Clinical interventions Pharmacotherapy Resources Outline Smoking and its effects on IBD
More informationEMERGING ISSUES IN SMOKING CESSATION
EMERGING ISSUES IN SMOKING CESSATION Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe, CM, MD University
More informationTrends in electronic cigarette use in England
Trends in electronic cigarette use in England Robert West Jamie Brown Emma Beard University College London Updated 14 th April 215 Background Electronic cigarette use has become prevalent in many countries
More informationLearning Objectives 4/3/2018 UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION BACKGROUND
UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION Richard Dang, PharmD, APh, BCACP Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Rory Kim, PharmD, BCACP Assistant Professor
More informationVarenicline versus transdermal nicotine patch for smoking cessation: results from a randomised openlabel
See Editorial, page 666 1 Hôpital Emile Roux, Assistance Publique-Hopitaux de Paris, Limeil-Brévannes; Centre d Enseignement, de Recherche et de Traitement des Addictions, Hôpital Paul Brousse, Paris;
More informationNational Native American AIDS Prevention Center
National Native American AIDS Prevention Center PATRICK ROBERTS HEALTH POLICY FELLOW PARTNERED WITH CINDY LANGHORNE CARING AMBASSADORS PROGRAM www.nnaapc.org www.nnaapc-hcv.org NNAAPC Advocacy Efforts
More informationMedication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019
Medication Management to Aid in Smoking Cessation Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 1 Learning Objectives: Review the prevalence of tobacco use. Describe tools
More informationSmoking Cessation: A readily modifiable risk factor
Robert L. Keith MD FCCP Associate Professor of Medicine Medical Director of Respiratory Therapy Eastern Colorado Health Care System University of Colorado Denver Smoking Cessation: A readily modifiable
More informationSupporting smokers with mental health problems
Collaboration for Leadership in Applied Health Research and Care South London (CLAHRC South London) Supporting smokers with mental health problems Ann McNeill, Professor of Tobacco Addiction Dr Debbie
More informationPharmacotherapy Safety and Efficacy in Adolescent Smoking Cessation
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Pharmacotherapy Safety and Efficacy in
More informationBASIC SKILLS FOR WORKING WITH SMOKERS
BASIC SKILLS FOR WORKING WITH SMOKERS Course Description Goals and Learning Objectives 55 Lave Ave No, Worcester, MA 01655 www.umassmed.edu/tobacco 2016 Basic Skills for Working with Smokers 1 Table of
More informationALL QUITLINE FACTS: An Overview of the NAQC 2009 Annual Survey of Quitlines
ALL QUITLINE FACTS: An Overview of the NAQC 2009 Annual Survey of The North American Quitline Consortium (NAQC), established in 2004, provides leadership and forums for health departments, quitline service
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More information